» Articles » PMID: 33878073

A Meta-analysis of Optimal Medical Therapy with or Without Percutaneous Coronary Intervention in Patients with Stable Coronary Artery Disease

Overview
Date 2021 Apr 20
PMID 33878073
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Whether percutaneous coronary intervention (PCI) improves clinical outcomes in patients with chronic angina and stable coronary artery disease (CAD) has been a continuing area of investigation for more than two decades. The recently reported results of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches, the largest prospective trial of optimal medical therapy (OMT) with or without myocardial revascularization, provides a unique opportunity to determine whether there is an incremental benefit of revascularization in stable CAD patients.

Methods: Scientific databases and websites were searched to find randomized clinical trials (RCTs). Pooled risk ratios were calculated using the random-effects model.

Results: Data from 10 RCTs comprising 12 125 patients showed that PCI, when added to OMT, were not associated with lower all-cause mortality (risk ratios, 0.96; 95% CI, 0.87-1.08), cardiovascular mortality (risk ratios, 0.91; 95% CI, 0.79-1.05) or myocardial infarction (MI) (risk ratios, 0.90; 95% CI, 0.78-1.04) as compared with OMT alone. However, OMT+PCI was associated with improved anginal symptoms and a lower risk for revascularization (risk ratios, 0.52; 95% CI, 0.37-0.75).

Conclusions: In patient with chronic stable CAD (without left main disease or reduced ejection fraction), PCI in addition to OMT did not improve mortality or MI compared to OMT alone. However, this strategy is associated with a lower rate of revascularization and improved anginal symptoms.

Citing Articles

Percutaneous coronary intervention versus optimal medical therapy for stable coronary artery disease: An umbrella review.

Soriano-Moreno D, Fernandez-Guzman D, Tuco K, Soriano-Moreno A, Ccami-Bernal F, Coico-Lama A Heliyon. 2024; 10(5):e27210.

PMID: 38486733 PMC: 10937673. DOI: 10.1016/j.heliyon.2024.e27210.


Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week.

Boden W, Marzilli M, Crea F, Mancini G, Weintraub W, Taqueti V J Am Coll Cardiol. 2023; 81(5):505-514.

PMID: 36725179 PMC: 10561495. DOI: 10.1016/j.jacc.2022.08.814.


The Treatment of Coronary Artery Disease.

Doenst T, Thiele H, Haasenritter J, Wahlers T, Massberg S, Haverich A Dtsch Arztebl Int. 2022; 119(42):716-723.

PMID: 35912444 PMC: 9835700. DOI: 10.3238/arztebl.m2022.0277.


Temporal trends in the efficacy of revascularization in stable ischaemic heart disease: A cumulative meta-analysis.

Farmakis I, Zafeiropoulos S, Doundoulakis I, Papazoglou A, Karagiannidis E, Giannakoulas G Am J Prev Cardiol. 2022; 10:100340.

PMID: 35478932 PMC: 9035395. DOI: 10.1016/j.ajpc.2022.100340.